Home
STOK
STOK News

Latest Stoke Therapeutics Inc. (STOK) News on January 19, 2025

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire

11 days ago

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results

BioPharma Dive

11 days ago

Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results

MT Newswires

12 days ago

Stoke Therapeutics Reports Alignment With Regulators for Dravet Syndrome Trial

MT Newswires

12 days ago

Wedbush Raises Stoke Therapeutics' Price Target to $19 From $17, Keeps Outperform Rating

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Business Wire

12 days ago

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Business Wire

13 days ago

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex

Zacks

24 days ago

The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex

4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

Zacks

a month ago

4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow

MT Newswires

a month ago

Chardan Initiates Coverage on Stoke Therapeutics With Buy Rating

Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth

Simply Wall St.

a month ago

Companies Like Stoke Therapeutics (NASDAQ:STOK) Are In A Position To Invest In Growth

MT Newswires

a month ago

Stoke Therapeutics Reports Durable Seizure Control With Zorevunersen in Dravet Patient

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Business Wire

a month ago

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug

Zacks

a month ago

STOK Shares Up on FDA's Breakthrough Tag for Dravet Syndrome Drug

MT Newswires

a month ago

Stoke Therapeutics' Zorevunersen Gets FDA Breakthrough Therapy Status in Dravet Syndrome

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

Business Wire

2 months ago

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

Business Wire

2 months ago

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond

Pharma Voice

2 months ago

An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond

Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks

2 months ago

Stoke Therapeutics (STOK) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade

Zacks

2 months ago

Wall Street Analysts Believe Stoke Therapeutics (STOK) Could Rally 66.84%: Here's is How to Trade

Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues

Simply Wall St.

2 months ago

Need To Know: Analysts Are Much More Bullish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenues

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

Zacks

2 months ago

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Business Wire

2 months ago

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

Zacks

3 months ago

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Zacks

3 months ago

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Stoke Therapeutics assumed with an Outperform at Leerink

TipRanks

3 months ago

Stoke Therapeutics assumed with an Outperform at Leerink

Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases

Insider Monkey

3 months ago

Stoke Therapeutics, Inc (STOK): Pioneering RNA Medicine for Genetic Diseases

MT Newswires

3 months ago

Stoke Therapeutics Files Mixed Shelf

GuruFocus.com

4 months ago

Skorpios Trust Reduces Stake in Stoke Therapeutics Inc

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Business Wire

4 months ago

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Business Wire

4 months ago

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Business Wire

5 months ago

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

Business Wire

5 months ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

5 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Stoke Therapeutics Second Quarter 2024 Earnings: Beats Expectations

Stoke Therapeutics eyes Phase III Dravet syndrome trial, as FDA releases hold

Clinical Trials Arena

5 months ago

Stoke Therapeutics eyes Phase III Dravet syndrome trial, as FDA releases hold

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Zacks

5 months ago

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Business Wire

5 months ago

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

6 months ago

Urogen Pharma (URGN) Expected to Beat Earnings Estimates: Should You Buy?

The 17% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 151%

Simply Wall St.

6 months ago

The 17% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 151%

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

6 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

7 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

We Think Stoke Therapeutics (NASDAQ:STOK) Can Afford To Drive Business Growth

Simply Wall St.

7 months ago

We Think Stoke Therapeutics (NASDAQ:STOK) Can Afford To Drive Business Growth

MT Newswires

7 months ago

Stoke Therapeutics Files Registration Statement For Sale of 10.8 Million Shares by Stockholders

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Business Wire

8 months ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares

GuruFocus.com

8 months ago

Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares

MT Newswires

8 months ago

Stoke Therapeutics Insider Sold Shares Worth $653,529, According to a Recent SEC Filing

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

8 months ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...

GuruFocus.com

8 months ago

Stoke Therapeutics Inc (STOK) Reports Q1 2024 Financial Results: A Closer Look at Challenges ...

MT Newswires

8 months ago

Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating

Stoke Therapeutics First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

8 months ago

Stoke Therapeutics First Quarter 2024 Earnings: Beats Expectations

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Zacks

8 months ago

Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Business Wire

8 months ago

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

MT Newswires

9 months ago

Stoke Therapeutics Appoints Thomas Leggett CFO

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

Zacks

9 months ago

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

Business Wire

9 months ago

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline

Zacks

9 months ago

Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Business Wire

9 months ago

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Business Wire

9 months ago

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Business Wire

10 months ago

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

Zacks

10 months ago

Stoke Therapeutics (STOK) Up on Upbeat Dravet Syndrome Study Data

Stoke Therapeutics Announces Proposed Public Offering

Business Wire

10 months ago

Stoke Therapeutics Announces Proposed Public Offering

Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients

Benzinga

10 months ago

Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated Patients

Stoke shares surge on updated results for Dravet drug

BioPharma Dive

10 months ago

Stoke shares surge on updated results for Dravet drug

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates

Zacks

10 months ago

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Business Wire

10 months ago

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

Business Wire

10 months ago

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)

Zacks

a year ago

Why Earnings Season Could Be Great for Stoke Therapeutics (STOK)

Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for

Zacks

a year ago

Analysts Estimate Zymeworks Inc. (ZYME) to Report a Decline in Earnings: What to Look Out for

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

a year ago

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

InvestorPlace

a year ago

7 Biotech Penny Stocks on the Verge of Clinical Trial Victory

Triple Threat: 3 Stocks to Buy for 3X Upside Potential

InvestorPlace

a year ago

Triple Threat: 3 Stocks to Buy for 3X Upside Potential

Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect?

Zacks

a year ago

Does Stoke Therapeutics, Inc. (STOK) Have the Potential to Rally 284.14% as Wall Street Analysts Expect?

Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?

Zacks

a year ago

Stoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?

18 Best 52-Week Low Stocks To Buy Now

Insider Monkey

a year ago

18 Best 52-Week Low Stocks To Buy Now

A Look Back at Footwear Retailer Stocks' Q3 Earnings: Genesco (NYSE:GCO) Vs The Rest Of The Pack

StockStory

a year ago

A Look Back at Footwear Retailer Stocks' Q3 Earnings: Genesco (NYSE:GCO) Vs The Rest Of The Pack

Gatos Silver Reports New Intercepts of High-Grade Mineralization at Cerro Los Gatos

GlobeNewswire

a year ago

Gatos Silver Reports New Intercepts of High-Grade Mineralization at Cerro Los Gatos

Institutions profited after Innodata Inc.'s (NASDAQ:INOD) market cap rose US$76m last week but retail investors profited the most

Simply Wall St.

a year ago

Institutions profited after Innodata Inc.'s (NASDAQ:INOD) market cap rose US$76m last week but retail investors profited the most

Ezcorp (EZPW) Flat As Market Gains: What You Should Know

Zacks

a year ago

Ezcorp (EZPW) Flat As Market Gains: What You Should Know

Financial Statement Series: Fisker Stock Analysis

Motley Fool

a year ago

Financial Statement Series: Fisker Stock Analysis

Gritstone bio (NASDAQ:GRTS) investors are sitting on a loss of 87% if they invested three years ago

Simply Wall St.

a year ago

Gritstone bio (NASDAQ:GRTS) investors are sitting on a loss of 87% if they invested three years ago

MasterCraft Boat Holdings, Inc. to Webcast Fiscal Second Quarter 2024 Earnings Conference Call Wednesday, February 7, 2024

GlobeNewswire

a year ago

MasterCraft Boat Holdings, Inc. to Webcast Fiscal Second Quarter 2024 Earnings Conference Call Wednesday, February 7, 2024

Gilead Sciences, Citi, Digital World Acquisition: Top Stocks

Yahoo Finance Video

a year ago

Gilead Sciences, Citi, Digital World Acquisition: Top Stocks

Trump-linked stocks soar after DeSantis throws in the towel

Reuters

a year ago

Trump-linked stocks soar after DeSantis throws in the towel

Consensus Cloud Solutions to Host Q4 and 2023 Year End Investor Call on February 21, 2024

Business Wire

a year ago

Consensus Cloud Solutions to Host Q4 and 2023 Year End Investor Call on February 21, 2024

W&T Offshore Announces Closing of Accretive Acquisition of Six Gulf of Mexico Fields

GlobeNewswire

a year ago

W&T Offshore Announces Closing of Accretive Acquisition of Six Gulf of Mexico Fields

3 Things to Know About Dutch Bros Stock

Motley Fool

a year ago

3 Things to Know About Dutch Bros Stock

The past year for Arrow Financial (NASDAQ:AROW) investors has not been profitable

Simply Wall St.

a year ago

The past year for Arrow Financial (NASDAQ:AROW) investors has not been profitable

Analysts Expect Breakeven For Theravance Biopharma, Inc. (NASDAQ:TBPH) Before Long

Simply Wall St.

a year ago

Analysts Expect Breakeven For Theravance Biopharma, Inc. (NASDAQ:TBPH) Before Long

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

a year ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Funko and Goliath Announce Exclusive Global Deal for Funko Games

Business Wire

a year ago

Funko and Goliath Announce Exclusive Global Deal for Funko Games

Cantaloupe, Inc. to Report Second Quarter Fiscal Year 2024 Results on February 8, 2024

Business Wire

a year ago

Cantaloupe, Inc. to Report Second Quarter Fiscal Year 2024 Results on February 8, 2024

Calculating The Fair Value Of Vishay Precision Group, Inc. (NYSE:VPG)

Simply Wall St.

a year ago

Calculating The Fair Value Of Vishay Precision Group, Inc. (NYSE:VPG)

Julie Andrews Begins as New Chief Financial Officer at Orthofix

Business Wire

a year ago

Julie Andrews Begins as New Chief Financial Officer at Orthofix

Groupon (GRPN) Is Attractively Priced Despite Fast-paced Momentum

Zacks

a year ago

Groupon (GRPN) Is Attractively Priced Despite Fast-paced Momentum

Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround

Zacks

a year ago

Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

Zacks

a year ago

Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results

Stagwell (STGW) and MNTN Partner to Forge a Unified Performance Marketing Ecosystem for Brands

PR Newswire

a year ago

Stagwell (STGW) and MNTN Partner to Forge a Unified Performance Marketing Ecosystem for Brands

VNET Welcomes New Executive Director to Board

PR Newswire

a year ago

VNET Welcomes New Executive Director to Board

Here's Why We Think Esquire Financial Holdings (NASDAQ:ESQ) Might Deserve Your Attention Today

Simply Wall St.

a year ago

Here's Why We Think Esquire Financial Holdings (NASDAQ:ESQ) Might Deserve Your Attention Today

Xponential (XPOF) Posts Robust 2023 Operating Highlights

Zacks

a year ago

Xponential (XPOF) Posts Robust 2023 Operating Highlights

Share on Social Networks: